Free Trial
NASDAQ:ELDN

Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis

Eledon Pharmaceuticals logo
$3.00 -0.06 (-1.80%)
As of 07/3/2025 01:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Eledon Pharmaceuticals Stock (NASDAQ:ELDN)

Key Stats

Today's Range
$3.06
$3.16
50-Day Range
$2.60
$3.31
52-Week Range
$2.30
$5.54
Volume
194,685 shs
Average Volume
314,444 shs
Market Capitalization
$179.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

Eledon Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

ELDN MarketRank™: 

Eledon Pharmaceuticals scored higher than 51% of companies evaluated by MarketBeat, and ranked 655th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Eledon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Eledon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Eledon Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Eledon Pharmaceuticals are expected to decrease in the coming year, from ($0.81) to ($1.01) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eledon Pharmaceuticals is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eledon Pharmaceuticals is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Eledon Pharmaceuticals has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Eledon Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    2.53% of the float of Eledon Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Eledon Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.
  • Change versus previous month

    Short interest in Eledon Pharmaceuticals has recently decreased by 8.90%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Eledon Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Eledon Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.53% of the float of Eledon Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Eledon Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.
  • Change versus previous month

    Short interest in Eledon Pharmaceuticals has recently decreased by 8.90%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      12.30% of the stock of Eledon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      56.77% of the stock of Eledon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Eledon Pharmaceuticals' insider trading history.
    Receive ELDN Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

    ELDN Stock News Headlines

    This Signal Only Flashes Once Every 4 Years – And It Just Triggered
    This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
    See More Headlines

    ELDN Stock Analysis - Frequently Asked Questions

    Eledon Pharmaceuticals' stock was trading at $4.12 at the beginning of the year. Since then, ELDN stock has decreased by 27.1% and is now trading at $3.0050.

    Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) released its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.20.

    Eledon Pharmaceuticals' top institutional shareholders include Howard Financial Services LTD. (0.05%).
    View institutional ownership trends
    .

    Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Eledon Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Adobe (ADBE) and CrowdStrike (CRWD).

    Company Calendar

    Last Earnings
    5/14/2025
    Today
    7/05/2025
    Next Earnings (Estimated)
    8/18/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:ELDN
    Fax
    N/A
    Employees
    10
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $9.00
    High Stock Price Target
    $9.00
    Low Stock Price Target
    $9.00
    Potential Upside/Downside
    +199.5%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    2 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$36.18 million
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $1.98 per share
    Price / Book
    1.52

    Miscellaneous

    Free Float
    52,517,000
    Market Cap
    $179.94 million
    Optionable
    Optionable
    Beta
    -0.16
    (Almost)  Everything You Need To Know About The EV Market Cover

    Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

    Get This Free Report

    This page (NASDAQ:ELDN) was last updated on 7/6/2025 by MarketBeat.com Staff
    From Our Partners